R. Delva

Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP)

Stéphane Culine, Pierre Kerbrat, A. Kramar et al. · Annals of Oncology · 2007 · 207 citations

Medicine, Oncology, Urology +14

Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy

François‐Clément Bidard, Claire Mathiot, Armelle Degeorges et al. · Annals of Oncology · 2010 · 143 citations · Full text

Medicine, Cancer Biology, Oncology +17

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 128 citations

Medicine, Oncology, Breast Oncology +9

High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer

Frédérique Penault‐Llorca, R. Delva, Philippe Bougnoux et al. · Breast Cancer Research and Treatment · 2005 · 105 citations

Medicine, Oncology, Breast Oncology +16

Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial

Sylvie Négrier, David Pérol, Alain Ravaud et al. · Journal of Clinical Oncology · 2005 · 89 citations

Medicine, Immunology, Oncology +17